China's biotech industry is growing quickly, and the innovative BeiGene could be an opportunity in the space.
News & Analysis: BeiGene
Shares tumble in response to an industry megamerger.
Whether you're in the U.S. or China, immuno-oncology is one of the hottest areas in biotech right now.
A third-quarter report and a couple of priority reviews from the China Food and Drug Administration encouraged investors.
A slew of investor updates last month added about $2 billion to the company's market cap.
It hasn't yet received a lot of media attention, but BeiGene has an absolutely huge opportunity in China's nascent biotechnology market.
Find out how these companies have defied a choppy market.
Find out how these three put up huge gains while their peers struggled.
These two highfliers have risen roughly fourfold over the past year. Here's how they could keep it going.
The FDA recently approved a groundbreaking new HIV treatment, and it isn't from Gilead or Glaxo.